Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent
Cancer cells often accumulate spontaneous and treatment-induced DNA damage i.e. potentially lethal DNA double strand breaks (DSBs). Targeting DSB repair mechanisms with specific inhibitors could potentially sensitize cancer cells to the toxic effect of DSBs. Current treatment for glioblastoma includes tumor resection followed by radiotherapy and/or temozolomide (TMZ) - an alkylating agent inducing DNA damage. We hypothesize that combination of PARP inhibitor (PARPi) with TMZ in glioblastoma cells displaying downregulation of DSB repair genes could trigger synthetic lethality. In our study, we observed that PARP inhibitor (BMN673) was able to specifically sensitize DNA ligase 4 (LIG4)-deprived glioblastoma cells to TMZ while normal astrocytes were not affected. LIG4 downregulation resulting in low effectiveness of DNA-PK-mediated non-homologous end-joining (D-NHEJ), which in combination with BMN673 and TMZ resulted in accumulation of lethal DSBs and specific eradication of glioblastoma cells. Restoration of the LIG4 expression caused loss of sensitivity to BMN673+TMZ. In conclusion, PARP inhibitor combined with DNA damage inducing agents can be utilized in patients with glioblastoma displaying defects in D-NHEJ.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Oncotarget - 9(2018), 96 vom: 07. Dez., Seite 36867-36877 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Toma, Monika [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alkylating agent |
|---|
| Anmerkungen: |
Date Revised 08.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.26409 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM292557086 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM292557086 | ||
| 003 | DE-627 | ||
| 005 | 20240408231950.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.26409 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM292557086 | ||
| 035 | |a (NLM)30627327 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Toma, Monika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Cancer cells often accumulate spontaneous and treatment-induced DNA damage i.e. potentially lethal DNA double strand breaks (DSBs). Targeting DSB repair mechanisms with specific inhibitors could potentially sensitize cancer cells to the toxic effect of DSBs. Current treatment for glioblastoma includes tumor resection followed by radiotherapy and/or temozolomide (TMZ) - an alkylating agent inducing DNA damage. We hypothesize that combination of PARP inhibitor (PARPi) with TMZ in glioblastoma cells displaying downregulation of DSB repair genes could trigger synthetic lethality. In our study, we observed that PARP inhibitor (BMN673) was able to specifically sensitize DNA ligase 4 (LIG4)-deprived glioblastoma cells to TMZ while normal astrocytes were not affected. LIG4 downregulation resulting in low effectiveness of DNA-PK-mediated non-homologous end-joining (D-NHEJ), which in combination with BMN673 and TMZ resulted in accumulation of lethal DSBs and specific eradication of glioblastoma cells. Restoration of the LIG4 expression caused loss of sensitivity to BMN673+TMZ. In conclusion, PARP inhibitor combined with DNA damage inducing agents can be utilized in patients with glioblastoma displaying defects in D-NHEJ | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a LIG4 | |
| 650 | 4 | |a PARP inhibitor | |
| 650 | 4 | |a alkylating agent | |
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a synthetic lethality | |
| 700 | 1 | |a Witusik-Perkowska, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Szwed, Marzena |e verfasserin |4 aut | |
| 700 | 1 | |a Stawski, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Szemraj, Janusz |e verfasserin |4 aut | |
| 700 | 1 | |a Drzewiecka, Malgorzata |e verfasserin |4 aut | |
| 700 | 1 | |a Nieborowska-Skorska, Margaret |e verfasserin |4 aut | |
| 700 | 1 | |a Radek, Maciej |e verfasserin |4 aut | |
| 700 | 1 | |a Kolasa, Pawel |e verfasserin |4 aut | |
| 700 | 1 | |a Matlawska-Wasowska, Ksenia |e verfasserin |4 aut | |
| 700 | 1 | |a Sliwinski, Tomasz |e verfasserin |4 aut | |
| 700 | 1 | |a Skorski, Tomasz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 9(2018), 96 vom: 07. Dez., Seite 36867-36877 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2018 |g number:96 |g day:07 |g month:12 |g pages:36867-36877 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.26409 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2018 |e 96 |b 07 |c 12 |h 36867-36877 | ||